Actively Recruiting
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2022-06-02
1200
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating cardiorenal syndrome, a condition where injury to the heart or kidney causes dysfunction in the other organ. This syndrome has become increasingly common and complex, making treatment challenging. The study aims to understand the characteristics, causes, risk factors, and interventions across different stages of heart and kidney diseases to improve treatment approaches. Participants will be observed under guideline recommended routine treatment. The study includes patients with various types of cardiorenal syndrome classified into five subtypes based on expert consensus: acute and chronic heart-related kidney injury, acute and chronic kidney-related heart injury, and secondary syndrome involving simultaneous heart and kidney dysfunction. The study focuses on these subtypes without testing new drugs or procedures. During participation, patients will be monitored for hospitalizations due to worsening kidney or heart function and all-cause deaths over one year. Additional outcomes include progression to end-stage renal disease requiring dialysis and occurrences of acute kidney injury. Researchers will collect clinical data to analyze disease progression and treatment effects. The study started in 2016 and is expected to continue until 2027, with regular follow-ups to assess health status and treatment impact.
CONDITIONS
Brief Title
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with any type of cardiorenal syndrome based on KDIGO and ADQI expert consensus classifications
- Includes five subtypes: acute and chronic heart-related kidney injury, acute and chronic kidney-related heart injury, and secondary syndrome with simultaneous heart and kidney dysfunction
- Adults aged 18 years and older
You will not qualify if you...
- Pregnant or breastfeeding women
- Female patients planning pregnancy soon
- Patients unable to follow up regularly on medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants who undergo routine care are observed to track the progression of cardiorenal syndrome and related outcomes.
Regular follow-up visits depending on clinical needs
Trial Site Locations
Total: 1 location
1
Nanjing, China
Actively Recruiting
Research Team
Y
Yue Zhou, master of medicine
X
Xiao-xia Chen, master of medicine
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here